Document is current
Any future updates will be listed below
-
Authors
Harasim, Anna S.
Krone, Manuel
Tony, Hans-Peter
Gawlik, Micha
Witte, Torsten
Joos, Stefanie
Gernert, Michael
Schmalzing, Marc
Morbach, Henner
Schwaneck, Eva C. https://orcid.org/0000-0003-1935-2092
-
Funding
Funding for this research was provided by:
Takeda Pharmaceutical Company
- License Information
-
More Information
Article History
Received: 15 September 2020
Accepted: 22 December 2020
First Online: 6 January 2021
Compliance with Ethical Standards
:
: Anna S. Harasim, Manuel Krone, Micha Gawlik, and Stefanie Joos have no conflicts of interest. Hans-Peter Tony has received honoraria for consultation from Takeda/Shire. Torsten Witte has received honoraria for speaking at symposia from CSL Behring, Octapharma, and Shire. Michael Gernert has received financial support for attending symposia from AbbVie, Chugai, Hexal, Janssen, Lilly, Pfizer, and Roche. Marc Schmalzing has received honoraria for speaking at symposia, financial support for attending symposia, and research grants and honoraria for consultation from Baxalta. Henner Morbach has received honoraria for speaking at symposia from Shire/Takeda, CSL Behring; and honoraria for consultation from Shire/Takeda. Eva C. Schwaneck has received honoraria for speaking at symposia, financial support for attending symposia, and research grants and honoraria for consultation from Baxalta/Shire/Takeda.
: Approval was obtained from the ethics committees of University of Würzburg (file number 147/18-sc) and University of Hanover (file number 8279_BO_K_2019). The procedures used in this study adhere to the tenets of the Declaration of Helsinki.
: Informed consent was obtained from all individual participants included in the study.
